ToyosiOdenike

Toyosi Odenike, MBBS

Assistant Professor of Medicine, Section of Hematology/Oncology

Dr. Olatoyosi Odenike is an Assistant Professor of Medicine in the Section of Hematology/Oncology. She is an expert in the care of adults with leukemia, chronic myeloproliferative and myelodysplastic diseases, and lymphoma. She specializes in all types of treatment for these diseases, including stem cell transplantation.

Dr. Odenike is a member of the Institutional Review Board at the University of Chicago, the International Working Group for Myelofibrosis Research and Treatment, and a member of the Editorial Board for the American Journal of Hematology. She was also formerly a member of the National Institutes of Health Grant Review Panel on Myeloproliferative Disorders and Myelodysplastic Syndromes, and the Leukemia Research Foundation Medical Advisory Board in 2005. Dr. Odenike is also a recipient of numerous awards, including the Midwest Trainee Investigator Award (sponsored by the American Federation for Clinical Research), the American Cancer Society Institutional Award, and the American Society of Clinical Oncology (ASCO) Career Development Award.

Dr. Odenike’s research is focused on the clinical and translational investigation of novel therapeutic agents for patients with myeloid neoplasms, including acute and chronic leukemias. She is the principal investigator on a number of clinical trials investigating novel targeted agents in this patient population including epigenetic modulators and signal transduction inhibitors.

Selected Publications from 2010 – 2011

  • van Besien K, Schouten V, Parsad S, Smith S, Odenike O, Artz A. Allogeneic Stem Cell Transplantation in Renal failure. Engraftment and Prolonged Survival, but High Incidence of Neurologic Toxicity. Leuk Lymphoma [Epub ahead of print], 2011.
  • Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs [Epub ahead of print], 2011.
  • O’Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 51:2240-2249, 2010.
  • Godley LA, Njiaju UO, Green M, Weiner H, Lin S, Odenike O, Rich ES, Artz A, Van Besien K, Daugherty CK, Zhang Y, Le Beau MM, Stock W, Larson RA. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 51:995-1006, 2010.

Reviews/Editorials

  • Odenike O, Le Beau MM. The dawn of the molecular era of the myelodysplastic syndromes. N Engl J Med 364:2545-2546, 2011.
  • Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol 38:215-224, 2011.
  • Odenike O, Thirman MJ, Artz AS, Godley LA, Larson RA, Stock W. Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol 38:196-214, 2011.
  • Jain N, Odenike O. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother 11:3073-3084, 2010.
  • Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 10:23-36, 2010.

Selected Presentations

  • “Therapeutic Targeting of Epigenetic Changes in Myeloid Neoplasia”
    Invited Speaker for Grand Rounds, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University
    Chicago, IL
    March 2010
  • “Epigenetic and other Rational Therapeutic Approaches in Myeloproliferative Neoplasms”
    Invited Speaker for an ASCO Annual Meeting Education Session
    Chicago, IL
    June 2010
  • “The Biology of Leukemia and Myeloproliferative Disorders: Implications for Treatment” Invited Chair of an ASCO Annual Meeting Education Session
    Chicago, IL
    June 2010
  • “Leukemia and Plasma Disorders”
    Invited Speaker for the Leukemia Session at Best of ASCO Meeting
    Boston, MA
    July 2010
  • “Epigenetic Targeted Therapies in Myelofibrosis”
    Invited Speaker at the Fifth International Workshop on CML and MPN
    Orlando, FL
    December 2010
  • Invited Speaker for Myeloproliferative Diseases and CML, Highlights of ASH, American Society of Hematology
    Washington DC
    January 2011
  • Invited speaker at the 5th Biennial Workshop on the Clinical Translation of  Epigenetics in Cancer Therapy
    San Diego, CA
    January 2011
  • Invited speaker at the Leukemia Research Foundation Town Hall Meeting
    Chicago, IL
    January 2011
  • Invited Speaker for Myeloproliferative Diseases and CML, Highlights of ASH, American Society of Hematology
    San Diego, CA
    February 2011
  • “Update on Phase II Trial of Decitabine in Myelofibrosis”
    Invited Speaker at the National Cancer Institute Cancer Therapy Evaluation Program Bethesda, MD
    March 2011
  • “Targeted Molecular Treatments for Leukemia and Lymphoma: The Case for Personalized Therapy”
    Invited Speaker at the Treatment Options for Blood Cancer Patient Conference, Leukemia Research Foundation
    Chicago, IL
    May 2011
  • “Therapeutic Targeting of Epigenetic changes in Myeloid Neoplasia”
    Invited Speaker for the Division of Hematology/Oncology Research Seminar, University of Miami School of Medicine and Sylvester Comprehensive Cancer Center
    Miami, FL
    May 2011
  • CML and Ph- Myeloproliferative Diseases Poster Discussion
    Invited Speaker and Discussant at the ASCO Annual Meeting
    Chicago, IL
    June 2011